(Q43875360)

English

Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering

scientific article published in February 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

27 November 2017

Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering (English)

1 reference

Europe PubMed Central

27 November 2017

ocular hypertension

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Steven T Simmons

1

1 reference

Europe PubMed Central

27 November 2017

Melissa L Earl

2

1 reference

Europe PubMed Central

27 November 2017

Alphagan/Xalatan Study Group

3

1 reference

Europe PubMed Central

27 November 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 February 2002

1 reference

Europe PubMed Central

27 November 2017

1 reference

Europe PubMed Central

27 November 2017

109

1 reference

Europe PubMed Central

27 November 2017

2

1 reference

Europe PubMed Central

27 November 2017

307-14; discussion 314-5

1 reference

Europe PubMed Central

27 November 2017

Shortterm “escape” and longterm “drift.”. The dissipation effects of the beta adrenergic blocking agents

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2801%2900936-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2801%2900936-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2801%2900936-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2801%2900936-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2801%2900936-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2801%2900936-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2801%2900936-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2801%2900936-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2801%2900936-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2801%2900936-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Prostaglandin analogues in the treatment of glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2801%2900936-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Additivity of prostaglandin F2 alpha-1-isopropyl ester to timolol in glaucoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2801%2900936-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2801%2900936-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and adverse effects of medications used in the treatment of glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2801%2900936-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of brimonidine 0.2% as adjunctive therapy for patients with glaucoma inadequately controlled with otherwise maximal medical therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2801%2900936-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The short-term effect of adding brimonidine 0.2% to timolol treatment in patients with open-angle glaucoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2801%2900936-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative acute effects of brimonidine 0.2% versus dorzolamide 2% combined with beta-blockers in glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2801%2900936-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The effectiveness and safety of brimonidine as mono-, combination, or replacement therapy for patients with primary open-angle glaucoma or ocular hypertension: a post hoc analysis of an open-label community trial. Glaucoma Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2801%2900936-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of brimonidine with latanoprost in the adjunctive treatment of glaucoma. ALPHAGAN/XALATAN Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2801%2900936-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2801%2900936-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Circadian intraocular pressure management with latanoprost: diurnal and nocturnal intraocular pressure reduction and increased uveoscleral outflow.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2801%2900936-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2801%2900936-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2801%2900936-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Additive effect of latanoprost, a prostaglandin F2 alpha analogue, and timolol in patients with elevated intraocular pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2801%2900936-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The additive effect of latanoprost to maximum-tolerated medications with low-dose, high-dose, or no pilocarpine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2801%2900936-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0161-6420(01)00936-8

1 reference

Europe PubMed Central

27 November 2017

release_54mdfvu2yjhihaltsk62q4lqyu

1 reference

https://api.fatcat.wiki/v0/release/54mdfvu2yjhihaltsk62q4lqyu

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

27 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43875360&oldid=2104075610"